Leerink Partnrs Issues Optimistic Estimate for AMLX Earnings

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX - Free Report) - Equities researchers at Leerink Partnrs upped their Q1 2025 EPS estimates for Amylyx Pharmaceuticals in a research report issued on Tuesday, May 6th. Leerink Partnrs analyst M. Goodman now anticipates that the company will post earnings per share of ($0.47) for the quarter, up from their previous forecast of ($0.52). Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Amylyx Pharmaceuticals' current full-year earnings is ($2.20) per share. Leerink Partnrs also issued estimates for Amylyx Pharmaceuticals' Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($1.90) EPS, FY2026 earnings at ($1.85) EPS, FY2027 earnings at ($1.80) EPS, FY2028 earnings at ($0.95) EPS and FY2029 earnings at ($0.40) EPS.

A number of other equities analysts have also commented on AMLX. Leerink Partners raised shares of Amylyx Pharmaceuticals from a "market perform" rating to an "outperform" rating and raised their target price for the stock from $4.00 to $10.00 in a research report on Wednesday, May 7th. Mizuho raised their target price on shares of Amylyx Pharmaceuticals from $7.00 to $8.00 and gave the stock an "outperform" rating in a research report on Wednesday. Finally, HC Wainwright raised their target price on shares of Amylyx Pharmaceuticals from $12.00 to $16.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. One analyst has rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $9.83.

Amylyx Pharmaceuticals Stock Down 2.9%

AMLX traded down $0.13 on Friday, reaching $4.36. 337,476 shares of the company traded hands, compared to its average volume of 1,220,524. The company has a market cap of $388.41 million, a P/E ratio of -1.14 and a beta of -0.60. Amylyx Pharmaceuticals has a one year low of $1.58 and a one year high of $7.27. The firm has a fifty day simple moving average of $4.09 and a two-hundred day simple moving average of $4.21.

Amylyx Pharmaceuticals (NASDAQ:AMLX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.45) by $0.03.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in AMLX. Geode Capital Management LLC lifted its stake in shares of Amylyx Pharmaceuticals by 17.5% during the third quarter. Geode Capital Management LLC now owns 551,039 shares of the company's stock worth $1,786,000 after buying an additional 82,173 shares during the period. Barclays PLC lifted its stake in shares of Amylyx Pharmaceuticals by 91.1% during the third quarter. Barclays PLC now owns 84,572 shares of the company's stock worth $274,000 after buying an additional 40,319 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Amylyx Pharmaceuticals by 144.4% during the third quarter. JPMorgan Chase & Co. now owns 140,559 shares of the company's stock worth $455,000 after buying an additional 83,048 shares during the period. Blue Trust Inc. lifted its stake in shares of Amylyx Pharmaceuticals by 232.1% during the fourth quarter. Blue Trust Inc. now owns 6,987 shares of the company's stock worth $26,000 after buying an additional 4,883 shares during the period. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Amylyx Pharmaceuticals during the fourth quarter worth $56,000. 95.84% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, CEO Joshua B. Cohen sold 21,490 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $3.47, for a total value of $74,570.30. Following the completion of the sale, the chief executive officer now directly owns 3,355,280 shares in the company, valued at $11,642,821.60. This trade represents a 0.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Bernhardt G. Zeiher acquired 10,000 shares of the stock in a transaction dated Thursday, March 20th. The shares were bought at an average price of $3.70 per share, with a total value of $37,000.00. Following the completion of the purchase, the director now directly owns 10,000 shares of the company's stock, valued at approximately $37,000. This trade represents a ∞ increase in their position. The disclosure for this purchase can be found here. Insiders sold a total of 48,980 shares of company stock worth $168,627 over the last three months. Corporate insiders own 11.70% of the company's stock.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.